INTRODUCTION
B Cell-Chronic Lymphocytic Leukemia (B-CLL), accounts for the most common chronic leukemia of adult in the western [1, 2] . However, in Asian countries it is uncommon and accounts for less than 10% cases [3] . Similarly, in Pakistan it has frequency of 9.7% amongst all the leukemia [4] . It is usually predominates in elderly with median age of onset of 65 years [5] , however 10% of CLL patients are usually less than 55 years of age. The phenotypic presentation of this disease is extremely heterogeneous ranging from indolent disease to rapidly progressive requiring immediate treatment. Majority of patients have stage 0 or 1 at presentation (Rai/Binet staging system). New biological prognostic markers such as ZAP-70 & CD-38 are independent predicable indicators of disease behavior [6] . ZAP-70 protein (defined as positive on at least 20% of B-cells), is actually a Zeta chain associated protein kinase. It has normal expression in T lymphocytes and natural killer cells, whereas on clonal B lymphocytes it appears as an aberrant marker [7, 8] . Patients with ZAP-70 positivity at diagnosis have poor prognosis as it is associated with aggressive nature of disease requiring early management with chemotherapy, short progression free survival and decreased overall survival [9, 10] .
CD-38 is a type II trans-membrane glycoprotein that functions as a receptor that induces proliferation & increases survival of CLL cells [11] . CD-38 positivity (defined as its presence on at least 30% of CLL cells) is an independent negative prognostic marker for clinical behavior in CLL [12, 13] . These patients have more aggressive disease and also show diminished response to chemotherapy [11] . In a study conducted by Gogia A, et al. ZAP-70 & CD-38 positivity was detected in 25 & 36% of Indian B cell CLL patients respectively [14] . On the other hand study conducted by Rozina et al. showed 13.5% ZAP-70 positive cases in Pakistani B-CLL patients [9] .
Our study was designed to see the frequency of both CD-38 & ZAP-70 positivity in our population, which would be helpful for risk stratification, patient counselling and compare it with local and international data. 
MATERIAL & METHODS

Patients
RESULTS
A total of 101 patients with B-Cell CLL were enrolled in the study. The median age of study population was 64 years (range 43-85 years). Majority of patients i.e., 69 out of 101 (68.32%) were males (Fig. 1).   Fig. (1) . Gender Distribution.
The frequency distribution of ZAP-70 and CD-38 positivity is presented in Table 1 . (Fig. 2) . Various studies have been published from our part of the world about the epidemiology, clinical and hematological markers and staging in CLL patients but even after the extensive search of literature we found that no study has been conducted so far in Pakistan that addresses the frequency of both CD-38 & ZAP-70 simultaneously. Limitation of our study include small sample size. A larger group of cohort would be a better representative of ZAP-70 & CD-38 prevalence in our population.
CONCLUSION
In our study, we concluded that ZAP-70 & CD-38 positivity was present in 2.97% & 33.66% of newly diagnosed B-CLL patients respectively. Moreover, CD-38 positivity was seen in more frequently in stage 3 and stage 4 of the disease at the time of diagnosis. So early screening for both CD38 and ZAP-70 in all newly diagnosed B-Cell CLL patients are surrogate markers of disease clinical spectrum which can guide about risk stratification, treatment outcome and overall survival.
